Novo Nordisk (NVO) has received the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use for the extension of the current indication for Saxenda, according to a Friday statement from the regulator.
The update in Saxenda's marketing authorization, once approved, will include the treatment of children aged 6 years to less than 12 years, the EMA said.
Saxenda is currently indicated as an "adjunct to healthy nutrition and increased physical activity for weight management," according to the statement.
Price: 67.52, Change: -0.65, Percent Change: -0.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.